中印医药产业竞争力比较研究

Comparative Study on the Competitiveness of Chinese and Indian Pharmaceutical Industries

为探寻提升中国医药产业的竞争力路径,以在国际医药市场占据重要地位的印度为比较对象,通过建立医药产业评价体系,利用GRA-TOPSIS法并引入RCA显示性比较优势指数,刻画中印医药产业竞争力演变特征及驱动因素。结果显示,在全球医药产业竞争中双方同属第二梯队,中印均实现了医药产业的迅速崛起并在细分领域互有领先。两国的医药产业综合竞争力驱动因素不尽相同,中国在医药产品、医疗器械方面竞争力更强,印度则更擅长于在以ANDA仿制药为代表的药物领域竞争。中国应在以原料药为代表的医药产品、医疗器械等领域持续扩大自身全球主导优势,在药物领域应加强对印度的学习并持续改善两国医药产业竞合结构,从国家到民间层面建立多级合作机制。

In order to explore the way to improve the competitiveness of China s pharmaceutical industry,this paper takes India,which holds an important position in the international pharmaceutical market,as the comparison object,through establishing the evaluation system of pharmaceutical industry,using THE GRA-TOPSIS method and introducing THE RCA indicative comparative advantage index,to describe the evolution characteristics and driving factors of the competitiveness of Chinese and Indian pharmaceutical industry.The results show that in the global pharmaceutical industry competition,both China and India belong to the second tier,and both China and India have achieved rapid rise and lead each other in segments.The driving factors for the comprehensive competitiveness of the pharmaceutical industry in the two countries are different.China is more competitive in pharmaceutical products and medical devices,while India is better at competing in the pharmaceutical field represented by generics of ANDA.China should continue to expand its global dominance in pharmaceutical products,medical devices and other fields represented by APIs.In the pharmaceutical field,China should strengthen its learning from India and continuously improve the competition and cooperation structure of the pharmaceutical industry of the two countries,and establish a multi-level cooperation mechanism from the national level to the private level.